52X Stock Overview
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.44 |
| 52 Week High | kr3.10 |
| 52 Week Low | kr1.88 |
| Beta | 0.59 |
| 1 Month Change | -10.95% |
| 3 Month Change | 12.96% |
| 1 Year Change | -3.94% |
| 3 Year Change | -39.75% |
| 5 Year Change | n/a |
| Change since IPO | 11.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 52X | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -6.9% | 2.4% | 1.2% |
| 1Y | -3.9% | -10.6% | 2.0% |
Return vs Industry: 52X exceeded the German Life Sciences industry which returned -10.6% over the past year.
Return vs Market: 52X underperformed the German Market which returned 2% over the past year.
Price Volatility
| 52X volatility | |
|---|---|
| 52X Average Weekly Movement | 6.5% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 52X has not had significant price volatility in the past 3 months.
Volatility Over Time: 52X's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 78 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| 52X fundamental statistics | |
|---|---|
| Market cap | €27.69m |
| Earnings (TTM) | €1.05m |
| Revenue (TTM) | €14.63m |
26.5x
P/E Ratio1.9x
P/S RatioIs 52X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 52X income statement (TTM) | |
|---|---|
| Revenue | kr171.17m |
| Cost of Revenue | kr17.18m |
| Gross Profit | kr153.99m |
| Other Expenses | kr141.76m |
| Earnings | kr12.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 89.96% |
| Net Profit Margin | 7.14% |
| Debt/Equity Ratio | 36.3% |
How did 52X perform over the long term?
See historical performance and comparison